Tuberculosis (TB), caused by Mycobacterium tuberculosis, spreads via aerosols and the first
encounter with the immune system is with the pulmonary-resident immune cells. The role of …

Abstract Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging due to high
treatment failure rate and adverse drug events. This study aimed to develop and validate a …

The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (MTB), the
bacterium responsible for tuberculosis (TB), has rekindled the interest in the role of nutritional …

Adequate drug exposure is important to ensure tuberculosis (TB) treatment efficacy and to
avoid acquired drug resistance. Although low drug exposure has been reported for most anti-…

Background: The pharmacokinetic/pharmacodynamics (PK/PD) target derived from the
hollow-fiber system model for linezolid for treatment of the multidrug-resistant tuberculosis (MDR-…

Aims: Bedaquiline is now recommended to all patients in the treatment of multidrug-resistant
tuberculosis (MDR-TB) using standard dosing regimens. As the ability to measure blood …

Aims To propose new exposure targets for Bayesian dose optimisation suited for high‐dose
rifampicin and to apply them using measured plasma concentrations coupled with a …

Although cycloserine is a recommended drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB) according to World Health Organization (WHO), few studies have reported …

Background Therapeutic drug monitoring (TDM) could improve current TB treatment, but few
studies have reported pharmacokinetic data together with MICs. Objectives To investigate …

Background Host innate immune cells have been identified as key players in the early
eradication of Mycobacterium tuberculosis and in the maintenance of an anti-mycobacterial …